<Emphasis Type="Italic">EGFR</Emphasis> and <Emphasis Type="Italic">p53</Emphasis> Status of Pulmonary Pleomorphic Carcinoma: Implications for <Emphasis Type="Italic">EGFR</Emphasis> Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy

Authors:	Yih-Leong Chang Chen-Tu Wu Jin-Yuan Shih Yung-Chie Lee

Affiliation:	(1) Department of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;(2) Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;(3) Department of Surgery, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan;

Abstract:	Background Pleomorphic carcinomas of the lung are uncommon malignant tumors composed of carcinomatous and sarcomatous components and are distinguished from other non-small-cell lung carcinomas by a more aggressive clinical course with early distant metastases and far worse survival. Epidermal growth factor receptor (EGFR) and p53 are common genes involved in the pathogenesis of non-small-cell lung carcinomas, but their roles in pleomorphic carcinomas are unclear. The potential clinical activity of EGFR-targeted therapy is also unknown.

Keywords:
本文献已被 PubMed SpringerLink 等数据库收录！